Loading company…
WhiteLab Genomics uses machine learning to develop genomic therapies and design tools.
Founded in 2019 and based in France, WhiteLab Genomics develops DNA, cell and RNA therapies using machine learning and deep learning. Its software supports target, payload and vector design, while its AI engine uses datasets to make in-silico predictions. In October 2026, the company raised EUR 23.2 million in Series B funding led by AXA Venture Partners, with Blast.Club, Yaday, Debiopharm Innovation Fund and Omnes Capital participating. The funding will support in vivo testing, non-viral delivery technologies and expansion in North America.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in